glatiramer (Copaxone)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Copaxone. (glatiramer acetate)

Indications

Dosage

single use vials:

Monitor

  • no monitoring recommended[2]

Adverse effects

Mechanism of action

Notes

  • one of 2 drugs accounting for 26% of total Medicare drug spending but just 1% of claims[5]

More general terms

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. 2.0 2.1 2.2 2.3 Medical Knowledge Self Assessment Program (MKSAP) 11, 17. American College of Physicians, Philadelphia 1998, 2015
  3. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  4. 4.0 4.1 Comi G et al, Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double- blind, placebo-controlled trial The Lancet, Early Online Publication, 7 October 2009 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19815268 doi:10.1016/S0140-6736(09)61259-9 http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2809%2961259-9/abstract
  5. 5.0 5.1 Walker J Small Number of Drugs Drive Big Medicare Bill The Wall Street Journal. April 20, 2015 http://www.msn.com/en-us/money/insurance/small-number-of-drugs-drive-big-medicare-bill/ar-BBiZz23
  6. 6.0 6.1 Fiore K NeuroBreak: First Copaxone Generic Okayed; Plus for Pain Tx News and commentary from the world of neurology and neuroscience. MedPage Today. October 10, 2017 https://www.medpagetoday.com/Neurology/GeneralNeurology/68443
    Sandoz announces US FDA approval and launch of Glatopa 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis. Sandoz. Feb 13, 2018 https://www.sandoz.com/news/media-releases/sandoz-announces-us-fda-approval-and-launch-glatopar-40-mgml-three-times-week
  7. Department of Veterans Affairs, VA National Formulary

Database